Hard To Treat Diseases (HTDS) Announces Initial Research Results on Potential MS Therapy
Posted on: Monday, 2 February 2009, 09:34 CST
Research results with animal testing encouraging
Testing involved the use of a combination of drugs; ribavirin and tiazofurin on animal test subjects. Administration of ribavirin and tiazofurin in combination attenuated or weakened the proliferation of autoreactive T lymphocytes and their infiltration into the nervous tissue that are involved in the destruction of myelin, oligodendrocytes and axons associated with MS. The tests succeeded in decreasing clinical symptoms and duration of the disease induced in experimental animals. These results are encouraging for the future MS therapy.
Also encouraging is the fact that the two drugs in question are currently used in treatment or undergoing clinical trials in relation to the treatment of other diseases. In particular, ribavirin is already in use in human clinical practice as an antiviral drug (VIRAZOL), and is very successful in treatment of respiratory syncicial virus in children, hepatitis C, SARS and HIV. Tiazofurin is in phase II of clinical trials as an anticancer drug.
Multiple sclerosis is a chronic disease with severe neurological symptoms, which often leads to complete disability and death. To date there is no suitable therapy for this heavy neurological disorder.
The company will provide further details as they become available.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet filings (www.pinksheets.com), and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation describing the risks of investing in penny stocks.
CONTACT: For scientific dialogue and inquiry only Andrea can be reached via e-mail at azconsulting2001@gmail.com; For any corporate matters the readers should contact the company directly at corporate@htdsmedical.com
SOURCE Hard to Treat Diseases
Source: PR Newswire
Related Articles
- Los Angeles County Launches Its Most Comprehensive Campaign Ever to Encourage HIV Testing
- Technology Could Help Treatment Of Diseases Of The Eye
- SciClone Reports Encouraging Results From Phase IIa Hepatitis Trial
- Seattle Genetics Reports Encouraging Results From Phase I Lymphoma Trial
- Aurelio Announces Highly Encouraging Metallurgical Test Results for Hill Copper Leach Project
- Lund Gold Ltd.: Initial Drilling Provides Encouraging Results at Carneirinho
- Natrol Highlights Published Clinical Treatment Protocol Recommending Red Clover Isoflavones As a Safe Alternative to Hormone Replacement Therapy
- AVANIR Pharmaceuticals Invites Investors to Second Quarter Conference Call and Provides Preliminary Results for Second Quarter and Business Highlights
- Point Therapeutics Provides Preliminary Results From Phase 2 Metastatic Pancreatic Cancer Study
- Tissera Reports Further Encouraging Results of Its Ongoing Large Animal Experiments of Pancreatic Xenotransplantation
 |
 |
User Comments (0)
RSS Feeds